Table 1.
Characteristics of included studies grouped alphabetically by index test type.
| Author, year | Country and income category | Study design | Study Pop | Age group | Number of subjects | Proportion with HIV infection | Proportion with HBV infection | Proportion female | Sample type | Sample condition |
|---|---|---|---|---|---|---|---|---|---|---|
| Abbott ARCHITECT HCV Ag | ||||||||||
| Buket, 2014 | Kazakhstan (B) | Cohort | Broad | Adults | 115 | Unknown | Unknown | 56.5% | Serum | Unknown |
| Chevaliez, 2014 | France (A) | Cross-sectional | Broad | Adults | 514 | Unknown | Unknown | 36.6% | Serum | Unknown |
| Cresswell, 2015 | UK (A) | Cohort | Broad | Adults | 111 | 100% | Unknown | 5.4% | Serum | Unknown |
| Descamps, 2012 | France (A) | Cross-sectional | Broad | Adults | 22 | Unknown | Unknown | 40.1% | Serum | Frozen |
| Durante-Mangoni, 2013 | Italy (A) | Cohort | Broad | Adults | 114 | 0 % | 0% | 43% | Serum | Frozen |
| Duy Thong, 2015 | Thailand (B) | Cohort | Broad | Adults | 189 | 44.9% | 0% | 28.6% | Serum | Frozen |
| Ergünay, 2011 | Turkey (A) | Cohort | Broad | Mixed | 272 | Unknown | Unknown | Unknown | Serum | Frozen |
| Florea, 2014 | Romania (B) | Cross-sectional | Broad | Adults | 76 | 0% | 0% | 75% | Serum | Frozen |
| Garbuglia, 2014 | Italy (A) | Cohort | Broad | Adults | 292 | 100% | 3.8% | 25.9% | Serum | Frozen |
| Gu, 2014 | China (B) | Cross-sectional | Broad | Unknown | 304 | Unknown | Unknown | Unknown | Whole | Unknown |
| Hadziyannis, 2013 | Greece (A) | Cross-sectional | Broad | Unknown | 105 | Unknown | Unknown | Unknown | Serum | Frozen |
| Heidrich, 2014 | Germany (A) | Cohort | Broad | Adults | 596 | Unknown | Unknown | 43% | Serum | Unknown |
| Kadkhoda, 2014 | Canada (A) | Cross-sectional | Broad | Adults | 154 | 1.3% | 0% | 50% | Serum | Unknown |
| Kesli, 2011 | Turkey (A) | Cohort | Healthy | Adults | 212 | Unknown | Unknown | 57.5% | Serum | Unknown |
| Köroglu, 2012 | Turkey (A) | Cohort | Broad | Unknown | 32 | Unknown | Unknown | 45.5% | Serum | Unknown |
| Kuo, 2012 | Taiwan (A) | Cohort | Broad | Adults | 405 | Unknown | Unknown | 52.6% | Serum | Unknown |
| Li Cavoli, 2012 | Italy (A) | Cohort | Broad | Adults | 92 | 1.1% | 2.2% | 41.3% | Serum | Unknown |
| Mederacke. 2009 | Germany (A) | Cohort | Broad | Unknown | 118 | 0% | 0% | Unknown | Serum | Unknown |
| Mederacke, 2012 | Germany (A) | Cross-sectional | Broad | Unknown | 237 | 49.50% | 50.50% | Unknown | Serum | Unknown |
| Medici, 2011 | Italy, Spain (A) | Cross-sectional | Broad | Unknown | 1480 | Unknown | Unknown | 52.6% | Serum | Frozen |
| Medici, 2016 | Italy (A) | Cross-sectional | Broad | Adults | 188 | Unknown | Unknown | 44.25% | Serum | Unknown |
| Miedouge, 2010 | France (A) | Cohort | Broad | Unknown | 2850 | Unknown | Unknown | Unknown | Serum | Frozen |
| Mixson-Hayden | USA (A) | Cohort | Broad | Unknown | 551 | Unknown | Unknown | Unknown | Serum | Frozen |
| Murayama, 2012 | Japan (A) | Cross-sectional | Broad | Unknown | 80 | Unknown | Unknown | Unknown | Plasma | Frozen |
| Ottiger, 2013 | Switzerland (A) | Cross-sectional | Broad | Adults | 97 | 6% | 0% | 38.1% | Plasma | Frozen |
| Park, 2010 | South Korea (A) | Cohort | Broad | Adults | 282 | Unknown | Unknown | 49.3% | Serum | Unknown |
| Reyes-Méndez, 2014 | Mexico (B) | Cross-sectional | Broad | Unknown | 211 | Unknown | Unknown | Unknown | Serum | Unknown |
| Rouet, 2015 | Gabon (B) | Cross-sectional | Broad | Adults | 54 | 100.00% | Unknown | 70.1% | Plasma | Frozen |
| Russi, 2014 | Italy (A) | Cohort | Broad | Adults | 102 | 0% | 0% | 78.4% | Serum | Frozen |
| Tedder, 2013 | UK (A) | Cohort | Broad | Unknown | 54 | 0% | 0% | Unknown | Plasma | Frozen |
| van Helden, 2014 | Germany (A) | Cross-sectional | Broad | Unknown | 3558 | 4.40% | 6.60% | Unknown | Serum | Unknown |
| Vanhommerig. 2015 | Netherlands (A) | Cohort | Broad | Unknown | 93 | 100.00% | Unknown | 0% | Serum | Unknown |
| Vermehren, 2012 | Germany (A) | Cohort | Broad | Adults | 160 | 0% | 0% | 54% | Serum | Frozen |
| EIKEN Lumispot HCV Ag | ||||||||||
| Saito, 2003 | Japan (A) | Cross-sectional | Broad | Unknown | 155 | Unknown | Unknown | Unknown | Serum | Frozen |
| Murayama, 2012 | Japan (A) | Cross-sectional | Broad | Unknown | 80 | Unknown | Unknown | Unknown | Plasma | Frozen |
| Fujirebio Lumipulse Ortho HCV Ag | ||||||||||
| Murayama, 2012 | Japan (A) | Cross-sectional | Broad | Unknown | 80 | Unknown | Unknown | Unknown | Plasma | Frozen |
| Hunan Jynda Bioengineering Group HCV Core Ag ELISA | ||||||||||
| Lu, 2007 | China (B) | Cohort | Broad | Unknown | 191 | Unknown | Unknown | Unknown | Serum | Unknown |
| Ouyang, 2006 | China (B) | Cross-sectional | Broad | Unknown | 149 | Unknown | Unknown | Unknown | Serum | Unknown |
| Zhang, 2007 | China (B) | Cohort | Healthy | Unknown | 11 | Unknown | Unknown | Unknown | Serum | Frozen |
| Zhu, 2010 | China (B) | Cross-sectional | Broad | Mixed | 173 | Unknown | Unknown | Unknown | Serum | Unknown |
| Ortho ELISA-Ag | ||||||||||
| Agha, 2004 | Egypt, Japan, Uzbekistan (AB) | Cohort | Broad | Unknown | 246 | Unknown | Unknown | Unknown | Serum | Unknown |
| El-Sayed, 2004 | Egypt (B) | Cross-sectional | Broad | Unknown | 50 | Unknown | Unknown | Unknown | Serum | Frozen |
| Letowska, 2004 | Poland (A) | Cohort | Healthy | Unknown | 124 | Unknown | Unknown | Unknown | Serum | Unknown |
| Nübling, 2002 | USA (A) | Cohort | Broad | Unknown | 52 | Unknown | Unknown | Unknown | Plasma | Frozen |
| Ohta, 2004 | Japan (A) | Cross-sectional | Broad | Unknown | 225 | Unknown | Unknown | Unknown | Serum | Unknown |
| Okazaki, 2008 | Japan (A) | Cohort | Broad | Unknown | 300 | Unknown | Unknown | 50.3% | Serum | Unknown |
HCV = Hepatitis C Virus, Cat = category, Pop = population, HIV = Human Immunodeficiency Virus, HBV = Hepatitis B Virus, Ag = Antigen, Ab = Antibody, ELISA = enzyme linked immunosorbent assay, EIA = enzyme immunoassay, UK = United Kingdom, USA = United States of America, A = High-income countries, B = Middle-income countries, C = Low-income countries by World Bank List of Economies (July 2015).